Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction

Journal of Urology

Volumn 188, Issue 2, 2012, Pages 668-674

  Kotera, Jun ^a   Mochida, Hideki ^a   Inoue, Hirotaka ^a   Noto, Tsunehisa ^a   Fujishige, Kotomi ^a   Sasaki, Takashi ^a   Kobayashi, Tamaki ^a   Kojima, Koki ^a   Yee, Shiyin ^b   Yamada, Yasuhiro ^a   Kikkawa, Kohei ^a   Omori, Kenji ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b Menlo Park and VIVUS   (United States)

Author keywords

4 ((3 chloro 4 methoxybenzyl)amino) 2 (2 (hydroxymethyl) 1 pyrrolidinyl) N (2 pyrimidinylmethyl) 5 pyrimidinecarboxamide; erectile dysfunction; penis; pharmacology; phosphodiesterase inhibitors

Indexed keywords

1 [6 CHLORO 4 (3,4 METHYLENEDIOXYBENZYLAMINO) 2 QUINAZOLINYL] 4 PIPERIDINECARBOXYLIC ACID; AVANAFIL; PHOSPHODIESTERASE; PHOSPHODIESTERASE 11; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG POTENCY; ENZYME ASSAY; ERECTILE DYSFUNCTION; IC 50; INTRACAVERNOUS PRESSURE; MALE; NERVE STIMULATION; NONHUMAN; PELVIC NERVE; PENIS NOCTURNAL TUMESCENCE; PRIORITY JOURNAL; RESPONSE TIME;

ANIMALS; CARBOLINES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERECTILE DYSFUNCTION; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MALE; PENILE ERECTION; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; PYRIMIDINES; SULFONES; TRIAZINES;

EID: 84863720636     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.03.115     Document Type: Article

References (21)

1. K. Omori, J. Kotera Overview of PDEs and their regulation Circ Res 100 2007 309
2. S.H. Francis, R. Zoraghi, J. Kotera Phosphodiesterase-5 molecular characteristics relating to structure, function, and regulation J.A. Beavo, S.H. Francis, M.G. Houslay, Cyclic Nucletotide Phoshodiesterases in Health and Disease 2007 CRC Press London 131 chap 7
3. R.A. Kloner Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction Circulation 110 2004 3149
4. T. Takahashi, T. Kanda, M. Inoue A selective type V phosphodiesterase inhibitor, E4021, protects the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension Life Sci 59 1996 PL 371
5. E. Takimoto, H.C. Champion, M. Li Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy Nat Med 11 2005 214
6. R.A. Kloner, G. Comstock, L.A. Levine Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors Expert Opin Pharmacother 12 2011 2297
7. J. Kotera, K. Fujishige, H. Michibata Characterization and effects of methyl-2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-2-pyridinylmethoxy)-4-(3,4, 5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (PDE5) Biochem Pharmacol 60 2000 1333
8. K. Fujishige, J. Kotera, K. Omori Striatum- and testis-specific phosphodiesterase PDE10A: Isolation and characterization of a rat PDE10A Eur J Biochem 266 1999 1118
9. T. Sasaki, J. Kotera, K. Yuasa Identification of human PDE7B, a cAMP-specific phosphodiesterase Biochem Biophys Res Commun 271 2000 575
10. M. Gamanuma, K. Yuasa, T. Sasaki Comparison of enzymatic characterization and gene organization of cyclic nucleotide phosphodiesterase 8 family in humans Cell Signal 15 2003 565
11. K. Yuasa, J. Kotera, K. Fujishige Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression J Biol Chem 275 2000 31469
12. T. Noto, H. Inoue, T. Ikeo Potentiation of penile tumescence by T-1032, a new potent and specific phosphodiesterase type V inhibitor, in dogs J Pharmacol Exp Ther 294 2000 870
13. F. Trigo-Rocha, W.J. Aronson, M. Hohenfellner Nitric oxide and cGMP: mediators of pelvic nerve-stimulated erection in dogs Am J Physiol 264 1993 H419
14. T. Saeki, H. Adachi, Y. Takase A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery J Pharmacol Exp Ther 272 1995 825
15. Y. Qiu, P. Kraft, E. Lombardi Rabbit corpus cavernosum smooth muscle shows a different phosphodiesterase profile than human corpus cavernosum J Urol 164 2000 882
16. M. Miyahara, M. Ito, H. Itoh Isoenzymes of cyclic nucleotide phosphodiesterase in the human aorta: characterization and the effects of E4021 Eur J Pharmacol 284 1995 25
17. S. Vemulapalli, R.W. Watkins, M. Chintala Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor Cardiovasc Pharmacol 28 1996 862
18. C. Wayman, S. Phillips, C. Lunny Phosphodiesterase 11 (PDE11) regulation of spermatozoa physiology Int J Impot Res 17 2005 216
19. H. Doh, C.Y. Shin, M. Son Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159 Arch Pharm Res 25 2002 873
20. J. Jung, S. Choi, S.H. Cho Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers Clin Ther 32 2010 1178
21. M. Limin, N. Johnsen, W.J. Hellstrom Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction Expert Opin Investig Drugs 19 2010 1427